Amgen pairs a diversified, high-margin blockbuster portfolio with MariTide’s obesity-market optionality, supporting a constructive five-year outlook despite biosimilar erosion and substantial acquisition-related debt.
Overview
Amgen is a large independent biotechnology company selling biologic therapies and small-molecule medicines across General Medicine, Inflammation/Immunology, Oncology/Hematology, Rare Diseases, and Biosimilars. Product sales contribute more than 95% of revenue; 17 commercial products annualize above $1.0 billion, and sales span roughly 100 countries, with the United States accounting for 73%. In Q3 2026, revenue rose 8% to $10.40 billion, beating consensus by $340 million, while non-GAAP EPS increased 14.4% to $6.45 and beat estimates by $0.69. Management raised FY2026 revenue guidance to $38.9–$39.7 billion and non-GAAP EPS to $22.90–$23.70. **A 47.3% non-GAAP operating margin and $3.7 billion of quarterly free cash flow underpin R&D and dividends**, while Repatha, EVENITY, TEZSPIRE, UPLIZNA, and IMDELLTRA drive growth against biosimilar erosion in mature products. Shares at $466.01 trade at 20.0x forward non-GAAP earnings, with a 2.16%–2.24% dividend yield. **MariTide Phase 3 progress is the principal near-term growth catalyst**, but debt and clinical, pricing, and biosimilar risks temper the outlook.